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Highlights 
 
 Profiling estrogen and its metabolites by mass spectrometry (MS) offers insights into 
health and disease 
 Low limits of quantification can be achieved by MS approaches, interfaced with GC 
or LC 
 Improvements in recovery, ion suppression and detection are discussed 
 Advances in current technologies for future method development strategies 
proposed. 
 
 
Abstract 
Estrogens and their bioactive metabolites play key roles in regulating diverse 
processes in health and disease. In particular, estrogen and estrogenic metabolites 
have shown both protective and non-protective effects on disease pathobiology, 
implicating the importance of this steroid pathway in disease diagnostics and 
monitoring.  All estrogens circulate in a wide range of concentrations, which in some 
patient cohorts can be extremely low. However, elevated levels of E2 are also reported 
in disease. For example, in pulmonary arterial hypertension (PAH) levels are elevated 
in men with idiopathic PAH and in postmenopausal women with PAH. Conventional 
immunoassay techniques have been under scrutiny for some time with their 
selectivity, accuracy and precision coming into question. Analytical methodologies 
such as gas and liquid chromatography coupled to single and tandem mass 
spectrometric approaches (GC-MS, GC-MS/MS, LC-MS and LC-MS/MS) have been 
developed to quantify endogenous estrogens and in some cases their bioactive 
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metabolites in biological fluids such as urine, serum, plasma and saliva. Liquid-liquid 
or solid-phase extraction approaches are favoured with derivatization remaining a 
necessity for lower volumes of sample. The limits of quantitation of individual assays 
vary but are commonly in the range of 0.5 – 5 pg/mL for estrone and estradiol, with 
limits of their bioactive metabolites being higher. This review provides an overview 
of current approaches for measurement of estrogens in biological matrices by MS, 
highlighting the advances in this field and the challenges remaining for routine use in 
the clinical and research environment.  
 
Abbreviations  
17beta-hydroxysteroid dehydrogenase type 1 & 2 (17βHSD1 and 17βHSD2); 1-(2,4-
dinitro-5-fluorophenyl)-4-methylpiperazine (PPZ); 1-(2, 4-dinitrophenyl)-4,4-di- 
methylpiperazinium (MPPZ); methylimidazole-2-sulfonyl chloride (MIS); 1,2-
dimethylimidazole-5-sulfonyl chloride (DMIS); 2-fluoro-1-methyl- pyridinium p-
toluene sulfonate (2-FMP); 2-fluoro-1-methyl- pyridinium p-toluene sulfonate (FMP-
TS); 2, 4 or 16-hydroxestradiol (2, 4 or 16-OHE2); 2, 4 or 16-hydroxestrone (2, 4 or 16-
OHE1); 2,4-dinitrofluorobenzene (DNBF); 2 or 4-methoxyestradiol (2 or 4-MeOE2); 2 
or 4-methoxyestrone (2 or 4-MeOE1); 3-bromomethyl-propyphenazone (BMP), 4-(4-
methyl-1-piperazyl)-3-nitrobenzoyl azide (APZ); 4-nitrobenzoyl chloride (NBCOCL); 
2-Hydroxyestrone-3-methyl Ether (2OHE-3ME); 16epiestriol (16epiOHE2); 
16ketoestriol (16ketoOHE2); 17epiestriol (17epiOHE2); atmospheric pressure 
chemical ionization (APCI); atmospheric pressure photoionization (APPI); catechol-
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O-methyltransferase (COMT); chemical ionization (CI); cytochrome p450 (CYP); 
dansyl chloride (DS); drift tube-ion mobility mass spectrometry (DT-IMS); estradiol 
(E2); estrone (E1); field asymmetric/differential- ion mobility mass spectrometry 
(FA/D-IMS); gas chromatography tandem mass spectrometry (GC-MS/MS); 
heptafluorobutyryl  chloride (HFB);  hydroxyestrogens (OHE);  ion mobility mass 
spectrometry (IMS); internal standard (IS); liquid chromatography tandem mass 
spectrometry (LC-MS/MS); Liquid Liquid Extraction (LLE); N-methyl-nicotinic acid 
N-hydroxysuccinimide ester (C1-NA-NHS);  N-(trimethylsilyl)imidazole (TMS); N-
methyl pyridinium-3-sulfonyl chloride (NMPS); N-methyl-N-(trimethylsilyl)-
trifluoroacetamide (MSTFA); N’-(5-fluoro-2,4-dinitrophenyl)-N,N-dimethyl-1,2- 
ethanediamine (PED); Not stated (NS); pentadecafluorooctanoyl chloride (PDFO); 
perfluorobenzoyl chloride (PFBO); pentaflurobenzoyl hydroxylamine hydrochloride 
(PFBHA); picolinoyl carboxylate (P);  pyridine-3-sulfonyl chloride (PS); solid phase 
extraction (SPE);   tandem quadrupole mass spectrometry (TQ-S); travelling wave- ion 
mobility mass spectrometry (TW-IMS); trifluoracetic acid (TFA); ultraflow LC (UFLC). 
Keywords 
estrogen; liquid chromatography tandem mass spectrometry; gas chromatography 
tandem mass spectrometry; extraction; derivatization 
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1 Introduction 
1.1 Estrogen Biochemistry  
Estrone (E1) and estradiol (E2) are the predominant circulating female sex steroids 
with multiple functions throughout the body. The third most common form in 
humans, estriol (E3 or 16OHE2), can be produced from estradiol or from estrone, the 
latter via the 16-hydroxyestrone (16OHE1) intermediate [1]. Estrogens can be 
synthesised on demand in some tissues from the major circulating adrenal steroids 
dehydroepiandrosterone (DHEA), andostenediol (A5), androstenedione (A4) and 
testosterone (T) [2] via the enzyme aromatase, Figure 1. Ovaries are the main 
production site of estrogens in premenopausal women, whereas tissues such as 
adipose play a greater role post-menopausally [3]. Estradiol is the most abundant 
hormone in pre-menopausal women, whereas estrone is more prevalent in post-
menopausal women and also in males, being generated from adrenal 
androstenedione. Isomers of estradiol exist in α and β configurations; 17β-estradiol 
(E2) refers to the main bioactive version whilst 17α-estradiol is generally thought less 
active [4]. Estriol increases throughout pregnancy being generated in the placenta. 
Aromatic oxidation of estrone and estradiol generates hydroxy-metabolites which are 
converted to methoxylated metabolites, but the exact circulating level of each remains 
largely unknown and under-investigated [5]. The levels of the bioactive metabolites 
are assumed lower than the main circulating estrogens, Table 1.  
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Table 1: Reference ranges of concentrations of estrogens in human plasma 
Group Age (Y) 
Estrone  
(pg/mL) 
Estradiol  
(pg/mL) 
Estriol (pg/mL) 
Female Children 0-15 ND - 200 ND - 40 ND 
Premenopausal 18-55 17 - 200 15 - 350 <10 
Pregnancy - >187 188 - 7192 80 - 130 
Postmenopausal >55 7 - 40 <10 ND 
Male Children 0-18 ND - 46 ND - 38 ND 
Males >18 10 - 60 10 - 40 <10 
*Concentration guidelines from Mayo medical laboratories (https://www.mayocliniclabs.com/test-
catalog/Clinical+and+Interpretive/84230 accessed 22/04/2019); Children <18; ND = Not detected; Y = 
years 
Throughout this review all estrogens and metabolites will be referred to collectively 
as estrogens. Estrone and estradiol are in equilibrium by interconversion by 17HSD1 
and 17HSD2 enzymes, catalyzing reduction or oxidation respectively at the C17 
position ketone/hydroxyl, and the balance largely favours estrone formation, Figure 
1. Further metabolism occurs via cytochrome p450 (CYP) enzymes, generating 
bioactive hydroxyl metabolites upon oxidation of the parent molecules at the C16, C4 
and C2 positions listed in the order of reactive preference [6]. In the C16 position, 
oxidation can occur via CYP1B1 [7] and16OHE1 formed can be interconverted with 
16OHE2. Both 16-hydroxy estrogens are further metabolised by conjugation. The 2- 
and 4-hydroxy-estrone and estradiol metabolites, collectively known as catechol 
estrogens (2OHE1, 4OHE1, 2OHE2 & 4OHE2), are rapidly converted (t 1/2= 90 
minutes [8]) to 2- and 4- methoxy–estrone and estradiol metabolites (2MeOE1, 
4MeOE1, 2MeOE2 and 4MeOE2) by the action of catechol-O-methyltransferase 
(COMT). Hydroxy and methoxy-estrone and estradiol metabolites are also 
maintained in constant equilibrium by 17HSD1 and 17HSD2 enzymes prior to their 
respective metabolism and removal from the body at the liver. Estrogens are 
converted to glucoronide and sulfate conjugates and for catechol metabolites also 
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form glutathione conjugates, all potential mechanisms of detoxification in hepatic and 
extra-hepatic sites [9].  
1.2 Influence of estrogens in disease pathobiology  
Epidemiological and experimental studies implicate estrogens in a number of diseases 
with the potential roles of bioactive metabolites becoming more prominent. For 
example, in cancer and cardiovascular fields E2, 16OHE1, 16OHE2, 2OHE2 and 
4OHE2 have been implicated in disease progression and 2OHE1, 4OHE1 4MeOE1, 
2MeOE2 and 4MeOE2 have shown protective roles. The remaining 2MeOE1 is 
thought to be inactive [5,10]. At site specific locations prior to removal, estrogens and 
the bioactive metabolites may act through genomic signalling cascades via estrogen 
receptors (ER) or alternatively by rapid non-genomic actions via G-protein coupled 
estrogen receptor 1 (GPER) and may directly alter protein signalling [11].  
Elevated estrogen levels in serum and plasma of women in particular have been 
associated with increased risk of breast [12,13], endometrial [14,15] and ovarian 
cancers [16,17], whilst in males estrogen-androgen imbalance is thought significant in 
the development of aggressive prostate cancers [18]. Emerging evidence implicates 
estrogen metabolism in the aetiology of diabetes [19] possibly explaining why in 
breast cancer obesity has proven to be a major contributing risk factor [20]. Most 
literature addresses E2 and E1; the bioactive estrogen metabolites remain less studied 
but are now gaining more prominence in each field. For example higher 16-hydroxy 
estrogen production has been linked to greater risk of diseases such as prostate cancer 
and pulmonary arterial hypertension (PAH)  [18].   
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In oncology, several factors link predisposition to metastasis to estrogen bioactivity. 
Clinically, three main scenarios are presented; in late menopause when site specific 
estrogen production and metabolism becomes more prominent; in hormone 
replacement therapy use where metabolic dysfunction occurs via increased 
exogenous supply; and thirdly in the presence of specific single nucleotide 
polymorphisms (SNPs) in aromatase that result in increased circulating plasma 
estradiol levels [12]. All scenarios lead to exacerbation of breast cancer symptoms [10]. 
Over and above changes in E1 and E2 signalling, changes urinary estrogen metabolite 
levels have been reported in mammary tumours with an emphasis on the 2/16-
hydroxyestrogen ratio [21]. Here, higher levels of 2-hydroxyestrogens compared to 
their mitogenic counterparts, 16-hydroxyestrogens, are associated with decreased risk 
of tumour growth and disease progression [22]. Specific bioactive metabolites are also 
linked to cardiovascular disease [23–25] with striking similarities to oncology 
findings. In PAH, a disease underpinned by gender differences, understanding the 
actions of estrogens and their metabolites may be key in elucidating the cause for 
female predominance. Research, in vitro and in vivo, with 16OHE1 has linked it to cell 
proliferation and vascular remodelling, significant phenotypic hallmarks of PAH [26–
28]. 16OHE1 exhibits a higher binding affinity and estrogenic potency than parent 
molecules at classical estrogen receptors [29], potentially activating the classical 
genomic signalling cascade and playing a pathogenic role in the pulmonary 
circulation. In this setting, increased levels in urine [30] also coincide with induction 
of smooth muscle proliferation within the pulmonary arteries [27]. Alternatively, 
metabolites like 2MeOE2 have demonstrated protective effects via disruption of 
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HIF1 signalling, decreasing mitogenic proliferative effects within lung fibroblasts in 
an apoptotic manner [31]. Interestingly a recent comprehensive study has further 
implicated elevated estradiol levels in male patients with PAH, linking this to poorer 
clinical outcomes [32]. Therefore, the potential consequences of estrogenic hormone 
imbalance within the body, at site-specific locations in both females and males, 
prompt investigation of the diverse profile of circulating estrogens with the aim of 
developing targeted therapeutic modulators within this sex hormone pathway.  
2 Quantification of estrogens 
This review will discuss approaches to analysis of unconjugated estrogens. 
2.1 Immunoassays  
Measurement of circulating estrogens in clinical diagnosis, research and monitoring 
often involves enzyme linked immunoassays (ELISAs) and radioimmunoassays 
(RIAs) [33,34] and has largely focussed on estradiol and estrone. Mainly these 
techniques are chosen due to their low cost and routine nature [35]. Both rely on the 
action of an antigen (estrogen) binding to specific antibodies; for ELISA, the detection 
of this interaction is accomplished via incubation with a substrate(s) known to emit a 
measurable product; for RIA, radioactive scintillation counting is applied. These 
methods can lack selectivity, being dependent on antibody characteristics, and often 
exhibit cross reactivity between different estrogens of interest and other species. This 
problem is particularly marked when measuring lower levels. High selectivity at low 
concentrations is a critical requirement for accurate analysis of estrone and estradiol 
particularly in men and older women, and the same rigour is needed to assay low 
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levels of bioactive estrogen metabolites [36,37]. Several studies for more abundant 
steroidal compounds such as cortisol, testosterone and vitamin D illustrate an 
imprecision between reported concentrations and a bias for false positives using 
immunoassays over a number of analytical methods [38–40]; this has led to the 
Endocrine Society issuing a consensus statement recommending avoidance of 
immunoassays for steroid hormone assays [41]. Therefore, development of robust 
analytical techniques capable of simultaneous quantification of panels of estrogens at 
low circulating concentrations becomes justified and here hyphenated mass 
spectrometry techniques have led the way. 
2.2 Analytical approach 
The journey of estrogen quantification began with researchers exploring a wide 
variety of diverse matrices using high performance liquid chromatography (HPLC), 
with a few publications reporting quantification of pharmaceutical estrogens within 
bio-fluids [42].  Transfer of methods for analysis of endogenous steroids by HPLC has 
proven difficult, due to insufficient sensitivity. The majority of analytical technologies 
that became available for clinical analysis of estrogens originally employed gas 
chromatography mass spectrometry (GC-MS). In more recent years, with the 
evolution of narrower bore liquid chromatography columns with smaller particle 
sizes, liquid chromatography tandem mass spectrometry (LC-MS/MS) has 
increasingly featured. Both approaches benefit from the use of stable isotope internal 
standards (IS) and have levels of specificity unrivalled by ELISAs and RIAs. Initially 
attempts to transfer to MS approaches were hampered due to sensitivity issues which 
can now be overcome by newer instrumentation, with increased selectivity and 
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sensitivity [34,43,44] and a number of successful approaches published (Tables 2 and 
3 and Figure 2). Only a few of these methods include the bioactive metabolites.  The 
critical and defining factors underpinning improvements in speed, sensitivity and 
reliability are tabulated and discussed below. 
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Table 2: Estrogen (unconjugated) quantification by GC-MS(/MS) 
Analyte Matrix 
Extraction 
Type 
V 
(mL) 
Derivatization 
Agent 
Inj 
V 
(µL) 
Column MS 
Mode 
(+/-) 
LOQ 
(pg/mL) 
Ref 
E1, E2 Serum LLE 1 TMS 1 
TR-50MS 
50% phenyl 
polysilphenylene-siloxane 
30 m × 0.25 mm  
(0.25 μm)  
Ion Trap 
EI-MS/MS 
+  13-21 [45] 
E1, E2 Serum LLE & SPE 0.25 
PFBHA 
PFBO 
NS 
DB-17HT, 50% 
phenylmethyl polysiloxane 
15 m × 0.25 mm (0.15 μm) 
Triple Quad 
CI-MS/MS 
- 0.5 [46] 
E2 Serum SPE 1 
PFBO 
PFBHA 
MSTFA 
NS 
DB-17 fused silica, 
Dimensions NS 
Triple Quad 
CI-MS/MS 
- 1.9 [37] 
E2 Plasma SPE 1 
PFBC 
MSTFA 
1 
(50% phenyl)-
methylpolysiloxane phase, 
15 m × 0.25 mm (0.25 µm) 
Triple Quad 
CI-MS/MS 
- 2.5 [47] 
E1, E2 
16OHE 
16Epi, 
KetoOHE2 
17EpiOHE2
2,4OHE 
2OHE-3ME 
2,4MeOE  
Urine SPE 2 
EOC  
PFP 
2 
MXT-1, Silcosteel-treated 
stainless steel, 30 m × 0.25 
mm (0.25 μm) 
Single Quad  
EI-MS 
+ 20-500 [48] 
Chemical Ionization (CI); Estrone (E1); Estradiol (E2); Gas Chromatography (GC);  Hydroxyestrogens (OHE); 2-Hydroxyestrone-3-methyl Ether 
(2OHE-3ME); 16epiestriol (16epiOHE2); 16ketoestriol (16ketoOHE2); 17epiestriol (17epiOHE2); Liquid Liquid Extraction (LLE); 
Methoxyestrogens (MeOE); N-methyl pyridinium-3-sulfonyl N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA); Not stated (NS); 
pentadecafluorooctanoyl chloride (PDFO); pentaflurobenzoyl hydroxylamine hydrochloride (PFBHA); perfluorobenzoyl chloride (PFBO); Solid 
phase extraction (SPE); Tandem mass spectrometry (MS/MS); N-(trimethylsilyl)imidazole (TMS)
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Table 3: Estrogen (unconjugated) quantification by LC-MS(/MS) 
Analyte Matrix 
Extraction 
Type 
V 
(mL) 
Agent 
Inj 
V 
(µL) 
LC Column 
Mobile Phase 
(A/B) 
MS 
Mode 
(+/-) 
LOQ 
(pg/mL) 
Ref 
E2 
Serum 
(Pooled) 
LLE 0.15 None 20 HPLC 
PoroShell 120  
SB-C18 
50 x 2.1 mm  
(2.7 μm) 
MeOH/H2O (+ 
0.1% FA or 2.5 
mM NH4OH) 
API 5000  
Triple Quad  
ESI vs APCI vs 
APPI-MS/MS 
+/- 
0.14 - 
0.68 
[49] 
E2 Serum LLE 0.2 DMIS 25 UHPLC 
phenyl-hexyl 
100 x 2.1 mm  
(1.7 μm)  
H2O/MeOH+ 
C7H8 
API 5000 
Triple Quad 
APPI-MS/MS 
+ 0.5 [50] 
E1, E2 
16OHE2 
Serum 
(Mouse) 
Online 
LLE 
0.1 None 1000 HPLC 
Supelcosil  
LC-8-DB 
250 x 4.6 mm (5 
μm) 
MeOH/H2O + 
C7H8 
API 5000  
Triple Quad  
APPI-MS/MS  
- 3 - 5 [51] 
E1, E2 Serum LLE 2 PS 20 HPLC 
phenyl-hexyl  
150 x 2.0 mm 
 (3 μm) 
H2O: 
(CH3CN+H2O) 
+ 0.1% FA 
API 4000 
Triple Quad 
ESI-MS/MS 
+ 10 [52] 
E1, E2 Serum LLE 0.2 DS 50 
2D-
HPLC 
C1 cartridge + 
Gemini phenyl 
100 x 2.0 mm  
(3 µm) 
H2O/MeOH + 
10 nmol/L 
H2O/CH3CN + 
10 nmol/L 
API 4000 
Triple Quad 
ESI-MS/MS 
- 1 [53] 
E1, E2 Plasma LLE 0.5 DS 15 HPLC 
Synergi,  
150 x 2.0 mm  
(4µMax-RP) 
CH3CN/H2O + 
0.1% FA 
API 3000 
Triple Quad 
APCI-MS/MS  
+ 6.3 - 11.9 [54] 
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Analyte Matrix 
Extraction 
Type 
V 
(mL) 
Agent 
Inj 
V 
(µL) 
LC Column 
Mobile Phase 
(A/B) 
MS 
Mode 
(+/-) 
LOQ 
(pg/mL) 
Ref 
E1, E2 
16OHE 
2,4OHE 
Serum * LLE 0.5 N/A 
 
10 
 
HPLC 
Zorbax 
C18  
250 x 4.6 mm  
(5 µm) 
CH3CN/H2O 
API 3000 
Tandem Quad 
axle  
ESI-MS/MS 
- 10-15 [55] 
E1, E2 Serum 
LLE + Strata 
X-SPE 
1 
PED 
PPZ 
MPED  
MPPZ 
3 HPLC 
YMC-C8  
150 x 2.0 mm (5 
µm) +  
Pro C18 RS 
150 x 2.0 (5 µm) 
CHCl3 /MeOH 
API 2000 
Triple Quad  
ESI-MS/MS 
+/- 0.55 - 9.2 [56] 
E1, E2 Serum LLE 0.5 DS 30 UHPLC 
Poroshell 120 SB-
C18, 30 x 2.1 mm 
(2.7 mm) + Zorbax 
SB-C18,  
50 x 2.1 mm (1.8 
µm) 
H2O/MeOH + 
0.2% FA 
6500 
 Triple Quad 
ESI-MS/MS 
+ 1 - 4 [57] 
E2 Serum LLE 0.29 None 5 Micro LC 
YMC Triart 
50 x 0.5 mm  
(3 µm) 
H2O/MeOH + 
0.05% NH4OH 
6500 
Triple Quad 
ESI-MS/MS 
- 3 [58] 
E1, E2 Serum LLE 0.5 None 100 HPLC 
Supelguard LC-8-
DB, 20 x 3.0 mm + 
LC-8-DB, 3.3cm × 
2.1 mm  
(3 μm) 
H2O/MeOH: 
CH3CN + 
NH4F 
5500 
Triple Quad 
ESI-MS/MS 
- 0.2 – 0.4 [59] 
E1, E2 
16OHE2 
Serum LLE 0.1 DS 20 UHPLC 
RP-18  
50 x 2.1 mm 
(1.7 μm) 
MeOH/H2O + 
0.2% FA 
4500  
Triple Quad 
ESI-MS 
+ 5 [60] 
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Analyte Matrix 
Extraction 
Type 
V 
(mL) 
Agent 
Inj 
V 
(µL) 
LC Column 
Mobile Phase 
(A/B) 
MS 
Mode 
(+/-) 
LOQ 
(pg/mL) 
Ref 
E2  
16OHE2 
MeOE2  
2,4OHE2  
Serum *LLE  0.1 NMPS 1 
nano 
AQUITY 
UHPLC 
BEH-130 C18 
150 x 100 mm  
(1.7 µm) 
H2O/CH3CN 
+0.1% FA 
TSQ Vantage 
Triple Quad 
+ 0.5 - 5  [61] 
E1, E2 
Serum/ 
urine 
LLE 0.01 
NBCO
CL 
DNBF 
10 HPLC 
YMC-Pack Pro  
C18 RS 
150 x 4.6 mm  
(5 μm) 
MeOH /H2O 
ThermoQuest 
Finnigan LCQ 
APCI-MS 
- 
2000 - 
3000 
[62] 
E1, E2 
16OHE 
16Epi, 
KetoOHE2 
17EpiOHE2
2,4OHE 
2,4MeOE 
Serum LLE 0.1 
MIS 
DS 
PS 
P 
25 HPLC 
Ascentis Express  
C18  
150 x 3.0 mm  
(2.7 μm) 
H2O/CH3CN 
+0.1% FA 
Orbitrap  
ESI-MS/MS 
+ 0.2 - 100 [63] 
E1, E2 
16OHE 
16Epi, 
KetoOHE2 
17EpiOHE2
2,4OHE 
2OHE-3ME 
2,4MeOE 
Serum 
(pooled) 
 
LLE  
 
2 
None 
vs 
C1-NA-
NHS 
5 UHPLC 
XDB-C18  
50 x 2.1 mm  
(1.8 μm) 
CH3CN 
A:5%, B:95% 
+10 mmol/L 
NH4CH3CO2 
TOF 
APCI vs ESI 
MS/MS 
+ or - 
360 - 
2340 
[64] 
E1, E2 
16OHE 
2,4OHE2 
MeOE2 
4OHE1 
2MeOE1 
Plasma SPE 0.25 BMP 10 HPLC 
Zorbax Extend 
C18 
150 x 4.6 mm  
(5 μm) 
H2O/CH3CN + 
0.1% FA 
6420A 
Triple Quad 
ESI-MS/MS 
+ 0.3 – 3.6 [65] 
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Analyte Matrix 
Extraction 
Type 
V 
(mL) 
Agent 
Inj 
V 
(µL) 
LC Column 
Mobile Phase 
(A/B) 
MS 
Mode 
(+/-) 
LOQ 
(pg/mL) 
Ref 
E2 Saliva 
PPE + 
Online SPE 
0.1 None 200 HPLC 
Shim-pack  
XR-ODS  
75 x 3 mm  
(2.2 µm) 
H2O/MeOH + 
2 mM 
NH4CH3CO2 
API 5000 
Triple Quad 
APCI-MS/MS 
+ 1 [66] 
E1, E2 Serum SPE 
0.5 -
1 
P 100 HPLC 
CD-C18  
150 x 3 mm  
(3 μm) 
CH3CN: 
CH3OH + 
HCOOH 
API 5000 
Triple Quad 
ESI-MS/MS 
+ 0.5 - 1 [67] 
E2 Serum SPE 3 DS 25 HPLC 
Zorbax Eclipse 
ZDB-C18  
150 x 2.1 mm  
(5 μm) 
H2O/CH3CN + 
1 mL/L 
CH3COOH 
API 4000 
Triple Quad 
ESI-MS/MS 
+ 1 [68] 
E1, E2 
16OHE2 
Serum 
Online  
SPE 
0.1 2-FMP 
300 
trap 
elute 
HPLC 
Kinetex1 XB-C18  
100 x 2.1 mm 
 (2.6 µm) 
H2O + 2.5% FA 
/MeOH + 20 
mM NH4HCO2 
8050 
Triple Quad  
ESI-MS/MS 
+ 3 - 7 [69] 
E1, E2, αE2 
16OHE 
MeOE 
Plasma SPE 0.5 MPPZ 30 UHPLC 
ACE Excel C18-
PFP 150 x 2.1 mm  
(2 µm) 
H2O/CH3CN + 
0.1% FA  
6500+ 
 Triple Quad 
ESI –MS/MS 
+ 2 - 10 [70] 
E1, E2 Plasma SPE 
0.5 - 
2 
FMPTS 20 UHPLC 
BEH C18  
50 x 2.1 mm  
(1.7 µm) 
Isocratic 
H2O/MeOH + 
0.1% FA 
5500 
Triple Quad 
ESI-MS/MS 
+ 2 [71] 
E1, E2, 
16OHE2 
Saliva SPE 0.25 None 30 
UFLC-
XR 
BEH C18-XP   
100 x 2.1 mm 
(2.5 µm) 
H2O/CH3CN + 
0.1 mM NH4F 
5500  
 Triple Quad  
ESI-MS/MS 
- 1 [72] 
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Analyte Matrix 
Extraction 
Type 
V 
(mL) 
Agent 
Inj 
V 
(µL) 
LC Column 
Mobile Phase 
(A/B) 
MS 
Mode 
(+/-) 
LOQ 
(pg/mL) 
Ref 
E2 Plasma SPE 0.5 None NS UHPLC 
HSS T3 C18  
100 x 2.1 mm 
 (1.8 µm) 
CH3CN/H2O  
TQ-S 
ESI-MS/MS 
+ 2 [73] 
E2 Serum 
Online  
SPE 
0.25 None 20 UHPLC 
C18 SB 
 30 x 2.1 mm  
(1.8 µm) 
H2O/MeOH 
TQ-S 
ESI-MS/MS 
- 3 [74] 
E1, E2 
16OHE2 
Serum SLE 0.1 None 90 HPLC 
Kinetex C18  
100 x 3.0 mm  
(2.6 µm) 
H2O/MeOH  
10% NH4OH 
(Post Column) 
5500 
Triple Quad 
ESI-MS/MS 
- 1 - 30 [75] 
E1, E2 
16OHE 
Serum 
Deprotein-
ation 
0.2 None 600 HPLC 
LC-8-DB, 
 3.3 cm × 3.0 mm 
 (3 μm) 
MeOH/H2O 
API 5000 
Triple Quad 
ESI-MS/MS 
- 1 - 2 [76] 
*Data reported for unconjugated estrogen quantification, Atmospheric pressure chemical ionization (APCI); atmospheric pressure 
photoionization (APPI); 3-bromomethyl-propyphenazone (BMP); 1,2-dimethylimidazole-5-sulfonyl chloride (DMIS); 2,4-dinitrofluorobenzene 
2,4-dinitrofluorobenzene (DNBF); dansyl chloride (DS); electrospray ionization (ESI); Estrone (E1); Estradiol (E2); Hydroxyestrogens (OHE); 2-
Hydroxyestrone-3-methyl Ether (2OHE-3ME); 16epiestriol (16epiOHE2); 16ketoestriol (16ketoOHE2); 17epiestriol (17epiOHE2); Liquid 1-
methylimidazole-2-sulfonyl (MIS); Liquid Chromatography (LC);  Liquid Liquid Extraction (LLE); Methoxyestrogens (MeOE); Methanol 
(MeOH); 1-(2,4-dinitro-5-fluorophenyl)-4,4- dimethylpiperazinium iodide (MPPZ); Mass Spectrometry (MS); 4-nitrobenzoyl chloride (NBCOCL); 
N-methyl-nicotinic acid N-hydroxysuccinimide ester (C1-NA-NHS); Not Stated (NS); pyridine-3-sulfonyl chloride (PS); picolinoyl carboxylate 
(P);  N’-(5-fluoro-2,4-dinitrophenyl)-N,N-dimethyl-1,2- ethanediamine (PED); 1-(2,4-dinitro-5-fluorophenyl)-4-methylpiperazine (PPZ); Solid 
phase extraction (SPE); trifluoracetic acid (TFA); tandem quadrupole mass spectrometry (TQ-S) 1,2- dimethylimidazole-5-sulfonyl chloride; 2-
fluoro-1-methyl- pyridinum p-toluene sulfonate (2-FMP); 2-fluoro-1-methyl- pyridinium p-toluene sulfonate (FMP-TS); Ultra Flow – LC (UF-LC); 
Ultra high performance–LC (UHPLC) 
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2.3 Methods of Detection and Quantitation 
Mass spectrometers interfaced with GC and LC have both been successfully applied 
to analyse estrogens in plasma and/or serum, with a number of validated methods 
reported, Table 2, following the general principles in Figure 2. It is important to 
recognize that when studying a family of related molecules that several estrogens may 
fragment to the same ion, and efficient chromatographic separation remains essential 
to avoids isobaric interferences, for example between isomers and isotopologues, 
notably [M+2] with groups of molecules interconverted from ketones to alcohols by 
oxidation/reduction. These possibilities must be planned for and thus potential 
sources of interference excluded upon method validation.  For MS, single quadrupoles 
were initially developed allowing one mass filter to be applied for selection of a single 
m/z ratio, in an approach known as selected ion monitoring (SIM). Advances in this 
technology led to the introduction of triple quadrupoles, allowing double mass 
filtering of initial precursor ions and their breakdown fragments (product ions) – 
known as multiple reaction mode (MRM).  Triple quadrupole MS operated in MRM 
rather than conventional SIM provide a much higher selectivity, with less interference 
from co-eluting matrix components and thus increased signal to noise ratio. This has 
allowed enhanced selectivity over wide dynamic ranges and improved accuracy and 
precision of an assay. Quantitation with high resolution or accurate mass analysers is 
possible but still in its infancy, held back in some cases by poorer quantitative 
performance due to narrower dynamic ranges [64]. Quantitative performance of these 
diverse analysers is variable, with Time-of-Flight instruments to date performing less 
well (Table 3) but some valuable methods coming forward with Orbitrap® technology 
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[30,63]. Their value in the field for structural identification and elucidation of 
fragmentation is however extremely important and well established [70,77]. 
2.4 GC-MS (/MS) 
In GC, the mobile phase is an inert gas (usually helium) and the stationary phase is a 
viscous liquid that coats the walls of the capillary column. Analytes must vaporize 
and then dissolve into the gas phase upon injection onto the GC column. Subsequently 
they are volatilized, and efficient phase transfer of steroids usually requires chemical 
derivatization. The derivatized steroids are resolved on the capillary column based on 
their relative affinities for the stationary phase and the temperature gradient applied 
to the GC oven. Stationary phases with phenyl groups have been most commonly 
used, as П- П interactions with the phenolic A-ring enables resolution of more 
challenging mixtures. Historically and still today greater resolving power is afforded 
with GC than LC, an important factor for improving isomer resolution and accurate 
and specific quantification.  
Chemical derivatization is applied with a range of reagents reported in Table 2. For 
MS analysis, both electron impact (EI) and chemical ionization (CI) have been used 
and of these, CI in conjunction with tandem MS is favoured in the literature. This is 
due to improved sensitivity brought about by electron capturing halogenated 
derivatization reagents. Accordingly the vast majority of GC-MS/MS approaches 
capable of detection of estrogens at low concentrations employ negative ion mode, 
although positive ionization has been employed in conjunction with ion-trap 
technology  successfully achieving a LLOQ of 13-21 pg/mL [45]. However, this would 
not be sufficiently low for certain patient cohorts, Table 1. Urinary analysis of 
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estrogens and their bioactive metabolites by GC typically involves extended sample 
preparation (two-step extraction) [48]. For analysis of E1 and E2 in serum, these types 
of extractions in conjunction with a derivatization show reliable detection, however 
extensive sample preparation can be required with both LLE and SPE for estrone and 
estradiol to allow detection at 0.5 pg/mL in 250 µL of rodent serum [46]. Approaches 
using solid phase extractions are most efficient for single step approaches with 
applications reporting limits of  1.9 pg/mL from 1 mL of serum from post-menopausal 
women [37] and 2.5 pg/mL in an application note from 1 mL serum [47]. Notably 
methods have not been reported for catechol and hydroxyl metabolites of estrogens 
in plasma by GC approaches, although in principle this should be achievable as they 
have been detected in urinary samples [48]. Although GC-MS/MS inherently allows 
enhanced chromatographic resolution, its routine application suffers from time 
consuming runs (30 min – 1 h), extensive sample preparation, use of high 
temperatures that may be detrimental to thermo-labile compounds and complex 
fragmentation of precursor ions within the MS source. Limits of quantification for a 
subset GC methods remain marginally out with the clinical range, with only one study 
in range reaching an LOQ of 0.5 pg/mL. This approach has still to be tested in human 
serum as opposed to rodent and relies on  extensive sample preparation [46]. LC-
MS(/MS), using softer ionization techniques, such as APCI, APPI or ESI are more 
likely to generate charged molecular ions. Thus, there has been much interest in 
bringing LC-MS(/MS), methods to the fore. This may provide higher-throughput, 
although it is worth debating whether adequate sensitivity can be achieved without 
derivatization. 
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2.5 LC-MS (/MS)  
LC-MS/MS is fast becoming the favoured approach for steroid analysis in clinical 
laboratories worldwide consequent to technological advances, in terms of efficiency 
in ion formation, transfer and detection. For the applications discussed here, reversed 
phase chromatography is almost exclusively used, using LC columns with 
hydrophobic stationary phase in conjunction with a polar mobile phase. C-18 columns 
[49,55–57,61,63,64,69,70,72,78] with their enhanced retention capabilities and robust, 
consistent manufacturing quality are preferred. Chemical alterations to bonded 
stationary phases, again exploiting interactions with the aromatic ring, can improve 
distinction of isomeric structures, typically required for the estrogen metabolites. 
Efficiency of separation can be enhanced by use of smaller particle sizes and longer 
columns, parameters which are inversely proportional to chromatographic efficiency 
[70]. Pairings of a wide variety of mobile and stationary phases are cited each with 
their own individual benefit. The careful choice of gradient elution parameters 
improves robustness of the assay, incorporating time for equilibration, elution and 
column cleaning. While ballistic gradients are attractive in reducing analysis times 
and in the cleaning phases, more subtle gradients are often necessary resolve isomers. 
Normally combinations of either methanol or acetonitrile and water are used. 
[49,54,70] with only one report using both acetonitrile and methanol [56].  
Given the low abundance of estrogens, it is unsurprising to see the use of triple 
quadrupole instruments, with their improved signal to noise, dominates over single 
quadrupole systems (Table 3). Positive-mode electrospray ionization (ESI) analyses 
are most prominent, at least for derivatized samples, Table 3, but alternative soft 
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ionization modes are also reported, namely atmospheric pressure chemical ionization 
(APCI), and the more recent atmospheric pressure photoionization (APPI) [49,79]. 
Estrogen analyses are reported in both positive and negative ionization modes 
dependent on the charge due to (de)protonation or coupled by derivatization and 
mobile phase modifiers such as formic acid, ammonium formate or acetic acid are 
frequently added.  
Limits of quantitation by LC-MS/MS are reported over a wide range of 0.14 - 3000 
pg/mL for estrone and estradiol. Inclusion of metabolites to create assay panels might 
be associated with a reduction in sensitivity due to lower dwell times for each scan 
but this is not that apparent in the applications reported in Table 3. Generally, 0.1 - 2 
mL of serum or plasma are required although 0.5 mL or below is desired for routine 
collection without excessive blood loss. The limits and volumes differ somewhat 
between ionization methods, Table 3. Examples include low limits of detection (0.5 – 
2.4 pg/mL) for metabolite panels in a study of breast cancer patients [65], with another 
study of pulmonary hypertensive patients ( 2 – 10 pg/mL) [70]. Negative mode is 
more commonly used in non-derivatized samples [36,51], capitalizing on the presence 
of a phenol within the estrogen structure with methods generally reporting limits of 
~1 pg/mL for estrone and estradiol. However ionization of non-derivatized estrogens 
in ESI mode occurs within charged droplets in competition with alternative species 
present in endogenous mixtures, which can cause ion suppression and this parameter 
must be evaluated in method development [80]. As an alternative, APCI is less liable 
to ion suppression as is APPI, using photons from a discharge lamp to aid ionization 
of molecules. Reported applications of APCI methodologies for estradiol analysis 
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have low limits of 0.5 pg/mL in serum [49] and 1 pg/mL in saliva [66] with limits for 
APPI reported as 3 – 5 pg/mL for estrone, estradiol and estriol in mouse serum [51]. 
Rahkonen et al presented a comprehensive comparison of all ionization modes and 
polarity combinations for estradiol analysis clearly demonstrating APPI in negative 
mode to have the lowest LOQ at 0.14 pg/mL. Using this approach, low concentrations 
in pooled serum were detected using ammonium hydroxide as an additive, Table 3 
[49]. Upon application to a clinical cohort samples (200 µL), a DMIS derivatization 
approach in conjunction with APPI was applied by the same group reporting limits in 
serum of 0.5 pg/mL  [50]. Notably addition of 2D chromatography boosts sensitivity 
for estrone and estradiol reducing LOQs tenfold [53] and  integration of this with APPI 
ionization might allow a further boost in quantification capabilities. As of yet APPI is 
not widely reported or available and, although advantages of APCI/APPI over ESI 
exist, the majority of routine analytical assays applied in clinical laboratories use ESI, 
creating a deterrent to regular exchange between MS interfaces and hindering their 
extended application. 
Alternative LC approaches such as ultra-flow LC (UFLC-MS) might be applied 
allowing reduction of flow rates (1 - 100 µL/min) combined with columns of smaller 
dimensions (ID; 0.1 and 1.0 mm). Advantages suggested include the ability to use 
smaller volumes of solvents which is of economic and environmental benefit, wider 
dynamic ranges and improved sensitivity [81]. A further application of microflow was 
introduced as the Ion Key® source from Waters, allowing direct infusion of 
microflow-LC into the MS with reported advantages of improved sensitivity, 
chromatographic performance and importantly robustness. This has been exemplified 
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in a technical report for estrone, estradiol and estriol, with LLOQs for non-derivatized 
steroids of 1 pg/mL, using negative-ESI with ammonium hydroxide as a mobile phase 
modifier for deprotonation. The authors here suggest clear analytical advantages over 
non-derivatized methods by conventional ESI-LC-MS/MS methods [81] but this is not 
always the case as shown in Table 3. In another study by Wang et al using nano-LC 
technology for analysis of serum in men, LOQs reached 0.5 pg/mL for estradiol and 
its metabolites except in the case of catechol estrogens whose limits were 5 pg/mL 
[61]. However, again this approach is not yet in routine use. Overall, a wider 
application of LC-MS/MS than GC-MS/MS for quantification of estrogen and its 
bioactive metabolites in plasma, serum and more recently in saliva has been 
demonstrated.  
2.6 Future Perspectives  
Simultaneous analysis of estrogen metabolite panels in biological matrices constitutes 
a difficult task. This subgroup of steroids, with their low abundance, have created and 
still present challenges for analysts in the search for high-throughput, facile and 
sensitive assays. With the advances in technology, this is now within grasp, but to 
quantify these molecules the sample volumes required are still relatively large and 
considerably more than for other steroids such as androgens.  In the future, aside from 
advances in standard GC or LC triple quadrupole technology, coupling of MS/MS to 
advanced chromatographic technologies such as supercritical fluid chromatography, 
ion mobility MS and micro-LC/nanospray might permit improved sensitivity and 
shorter run times than ever before.  Proponents of super critical fluid chromatography 
suggest that this separation method harnesses the advantage both LC and GC, 
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commonly employing methanol/carbon dioxide linear gradients as a mobile phase 
and resulting in faster separations and higher efficiencies than conventional GC. This 
non-polar solvent system has a low backpressure, allowing higher flow rates than LC 
due to the viscosity of the mobile phase being more similar to gas rather than liquid. 
Application to a panel of 15 estrogen metabolites for urine and serum was trialled for 
estrone, estradiol, estriol, 16-hydroxy, 16-keto, 2-hydroxy, 4-hydroxy, 2-methoxy, 3-
methoxy and 4methoxy – estrogens showing fast run times and 5 pg on column 
quantification limits [82]. This has yet to be validated for routine use and the 
availability of instrumentation is still restricted. Ion mobility mass spectrometry (IMS) 
provides an interface between the LC and MS/MS systems allowing separation of ions 
in the gas phase. Discrimination is based on their mobility differences in either high 
vs low electric fields and is dependent on their collisional cross sections. There are 
three main forms of IMS, drift tube (DT-IMS), travelling wave (TW-IMS) and field 
asymmetric/differential (FA/D-IMS). Of these, DIMS has been applied successfully 
to tissue samples for separation of estrone, estradiol and estriol from American eels 
[83]. In this case, ion mobility allowed efficient separation of structural isomers whilst 
reducing background noise over conventional ionization methods. For quantitation, 
IMS in principle may allow better signal to noise within the detector since species 
creating contemporary noise maybe separated from analytes through differential 
mobility. Isomeric estrogens have extremely similar mobility but the potential exists 
for derivatization to exaggerate structural difference and subsequently increasing 
separation between structural isomers [84]. As of yet this approach has not been 
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commonly employed, perhaps due to a lack of availability of dedicated systems in 
academic laboratories.  
2.7 Sample Preparation 
Prior to analytical quantification estrogens must be efficiently extracted from the 
matrix of choice. In the case of LC-MS/MS analysis ion suppression arises due to 
sample components, such as phospholipid and salt interference. Phospholipids 
remain the number one cause of diminished signal responses for analytical 
applications by LC-MS/MS. GC, however, does not suffer from this phenomenon due 
to the high energy nature of its ionization source, although remaining matrix 
components can cause undesirable deposits in the injector, start of the column or in 
the source and will lead reduced sensitivity and poor peak shapes. For either 
approach, sufficient removal of interfering compounds and lowering of background 
noise by sample pre-treatment is of paramount importance when approaching 
estrogen assay development. 
2.7.1 Liquid-liquid extraction (LLE) 
LLE provides an inexpensive approach to extract estrogens from the sample matrix 
exploiting their relative solubility in organic solvents. LLE has been used extensively 
and as a result is most common for the analysis of estrone and estradiol in serum 
[35,59]. Ultimate recovery and suppression of LLE approaches are dependent on the 
choice of extraction solvent. Solvents for extraction of estrogen into the organic phase 
include methyl tert-butyl ether (MTBE), ethyl acetate, diethyl ether, dichloromethane 
or mixtures of these organic solvents. Ethyl acetate is most commonly reported 
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affording high recoveries [85,86] and alongside MTBE, it yields a clean extract that 
avoids precipitation upon derivatization [87,88]. From Table 3, it can be seen LLE has 
been extensively applied to estrone and estradiol assays reporting low detection limits 
(0.001 – 5 pg/mL). However, for bioactive metabolites results are variable with higher 
limits than alternative sample preparation techniques (5 – 360 pg/mL). Additional 
drawbacks of LLE for routine testing also relate to its manual nature, commonly being 
more time-consuming and potentially exposing the analyst to high volumes of organic 
solvents. Sample loss through transfer between test tubes and plastic plates has been 
noted using LLE possibly contributing to inter-day imprecision [49].  
2.7.2 Solid Phase Extraction (SPE) 
Off-line solid phase extraction (SPE) is an attractive alternative to LLE, often employed 
for analysis of estrogen in water (i.e. for processing larger sample volumes), but also 
with effective application in the clinical setting in saliva , serum and plasma [54,68,72]. 
SPE extraction cartridges come embedded with a range of solid packing materials, 
which chemically separate the components of interest from the biological samples. 
Varieties of bed are commercially available containing reversed, normal, ion exchange 
or adsorption packing materials. For recovery of estrogens from aqueous sample 
matrices, reversed and ion exchange phases are recommended and are reported to be 
effective for clean up of plasma samples, Table 3. In principle, an SPE column 
containing an alternative packing material to the chromatography column holds 
advantages in improving sample clean up. SPE columns used for estrogen analysis 
often have C18 beds, but many commercial materials also exist such Oasis HLB®; most 
have hydrophobic characteristics optimal for interactions with the lipophilic features 
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of steroid hormones. HLB® operates over a wide range of pH values suitable for many 
compound classes. Choice of SPE column is based on achieving high recovery with 
low ion suppression, which can be difficult to achieve with complex matrices such as 
plasma [71]. A study by Faqehi et al 2016 suggested the use of Oasis MCX®, a cartridge 
housing a mixed mode cation exchange reverse phase bed, provides opportunities for 
additional sample clean up prior to the elution of the estrogen and this has been shown 
effective for a panel of the bioactive estrogens, including metabolites upon 
optimization of wash steps [70]. Other groups suggest  the use of C8 polypropylene 
columns conditioned and cleaned with 0.1% TFA improved recovery and diminished 
ion suppression for a panel of 10 estrogens [65].  Moving forward with SPE, newer 
products eliminate the need for conditioning and equilibration steps and availability 
of 96-well plates allow potential automation for robotic liquid handling systems. The 
main disadvantage with SPE for routine clinical analyses associates with the cost, as 
cartridges remain expensive. Moreover, coupling SPE and derivatization can 
introduce undesirable transfer steps and also losses depending on the type of 
collection container required to avoid adhesion (glass vs plastic). Glass inserts for 96-
well plates are expensive and only available for lower elution volumes. On-line SPE 
methods are available although less frequently reported as they can be complicated to 
develop without compromising the analytical chromatographic step [89]. However 
once the elution programme is optimized, directly linking the extraction processes to 
LC-MS/MS can improve recovery and sensitivity and minimize manual sample 
manipulation [90]. 
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2.7.3 Supported Liquid Extraction (SLE) 
Supported liquid extraction (SLE) opens doors to new approaches for extraction but 
as yet methods for estrogen analysis have been scarcely published, unlike with other 
steroids [91]. This strategy shows promise in company application notes [92] with 
successful application to androgen profiling for diseases such as congenital adrenal 
hyperplasia [93]. SLE applies the same solvent affinity principles as LLE whereby 
analytes are separated based on their partitioning into one solvent over another 
immiscible solvent and employs similar solvents. The support material consists of 
diatomaceous earth, a natural silica product (~90% silica), being an ideal material to 
absorb aqueous samples. This technique allows shorter load, wait and elute protocols 
to the generic SPE approaches, and the conditioning and equilibration steps of the 
cartridge bed are not needed. However, options for sample clean-up are limited in 
comparison to SPE. Again, SLE can be fully automated in 96-well formats but again 
there are challenges in interfacing with containers suitable for derivatization meaning 
non-derivatized method development would be favoured. One application for 
analysis of E1, E2 and E3 from 100 µL of plasma in the SLE 96 well format shows 
potential with low limits of 1, 3 pg/mL for estrone, estradiol respectively and 30 
pg/mL for estriol. This extraction method should now be tested with the wider panel 
of metabolites on more sensitive MS platforms.  
2.7.4 Derivatization  
Derivatization can be necessary prior to analysis of estrogens by MS, but with different 
goals for GC and LC.  In the case of GC it is necessary to enhance volatility and the 
introduction of halogen atoms enhances sensitivity of CI approaches [79]. For LC, 
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derivatization is often employed to aid formation of charged ions or generating 
permanently charged species. This increases sensitivity, and the greater the mass of 
the molecular ion holds further benefits for specificity. In GC-MS/MS the process 
adds poorly volatile reagents which cannot be easily removed. In both GC and LC, 
derivatization reagents can build up in the chromatographic column or within 
components of the mass spectrometer, thus, decreasing assay robustness. In LC, this 
may be addressed by initial flow can be diverted to waste, taking with it polar reagents 
and keeping the interface and source of mass spectrometer as clean as possible. In GC 
frequent inlet liner cleaning will be required. 
2.7.4.1 GC approaches 
In GC-MS/MS derivatization at the 3’ A ring position is favoured as reactions at the 
saturated aliphatic D ring largely do not improve sensitivity over non-derivatized 
samples illustrated in pentafluoropropionyl (PFP) or trimethylsilyl (TMS) derivatives 
for water analysis by GC-MS/MS [94,95]. The generation of PFB derivatives is the 
most commonly reported approach for estrone and estradiol analysis in serum, but 
cumbersome sample preparation steps have, however, hampered routine use 
[37,46,96].  
2.7.4.2 LC approaches without derivatization 
Development of analytical workflows of sufficient sensitivity without derivatization 
is challenging for clinical applications of estrogens, although they are desirable with 
sample preparation being shorter and less steps to introduce variation. Moreover, 
automation of derivatization by commercial robots is challenging to couple with 
robotic SPE/SLE workflows. However, a number of methods for estrone and estradiol 
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using LC-MS/MS are beginning to surface, (Table 2) as instrument technology 
improves. Methods achieving LOQs to compete with derivatization approaches have 
been reported using ammonium fluoride or ammonium hydroxide as mobile phase 
modifiers, promoting the formation of negative ions [59,72]. Recent analyses of 
estradiol report low LOQs, for example of 2 pg/mL using a UHPLC System coupled 
to a Xevo TQ-S [73]. Methods without derivatization are yet to be extended to include 
bioactive estrogen metabolites. If optimized successfully, validation of such assays 
would permit simplified sample preparation with the possibility of higher precision 
and throughput. 
2.7.4.3 LC approaches with derivatization 
Derivatization remains necessary for the majority of LC-MS assays of estrogens, 
overcoming poor ionization, limiting ion suppression and boosting signal intensity at 
low abundance. In reactions reported, introduction of easily ionizable groups or pre-
charged moieties improves sensitivity and permits the use of lower volumes of 
sample. As in GC-MS, the hydroxyl group of the phenolic A ring in the 3’ position is 
usually targeted, for the entire analyte panel. Successful derivatization methods 
commonly reported for analysis of estrone and estradiol include use of dansyl chloride 
[68,92,97,98], N-methyl-nicotinic acid N-hydroxysuccinimide ester [64], 2-fluoro-1-
methylpyridinium-p-toluene sulfonate [71], methyl-1-(5-fluoro-2, 4-dinitrophenyl)-
4,4-dimethylpiperazine [56,70], isomers of  1,2-dimethylimidazole-sulfonyl chloride 
[63,99], picolinoyl carboxylate [67], pyridine carboxylates [100], pyridine-3-sulfonyl 
chloride [52] and p-nitrobenzyl chloride [101]. From these, dansyl chloride has been 
the most common approach. However, the specificity of the fragment ions of dansyl 
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chloride derivatives is hindered for isobaric estrogen metabolite species since the 
product ions generated are identical, hailing from the derivative [63,97,98]. This is 
similar for alternative derivatives such as BMP [65], whereas methyl-propyphenazone 
derivatives generate identical product ions for seven estrogens whilst differing by m/z 
15 for the catechol metabolites. This source of non-specificty has been partially 
overcome by use of MPPZ and C1-NA-NHS, yielding a range of product ions, but they 
remain identical for certain groups of metabolites [64,70], since isomers undergo 
similar fragmentation patterns. These potentials for interference underpin a 
requirement for thorough evaluation of chromatographic methods, to eliminate 
possible co-elutants that may be mis-identified and lead to reporting of levels that are 
too high. It should not be forgotten that estradiol and estrone only differ by 2 mass 
units so 13C2 isotopologues used as internal standards will cross-signal if product ions 
are identical. It is not uncommon for multiple aliphatic and phenolic hydroxyl groups 
to be derivatized within the reaction especially within 16-hydroxy- and catechol 
estrogens. [56,102], yielding either doubly or triply charged species or isomeric 
derivatives. However, there may be a silver lining related to loss of predictable 
product ions in that, as tracking the loss of the associated mass/structural entity by 
accurate MS may allow identification of estrogenic species receptive to derivatization 
in an untargeted manner. Reactions will potentially proceed with all phenolic 
estrogens within complex matrices and thus pathway mapping through ‘omics 
profiling studies may reveal new metabolites. Finally, if derivatization is deemed 
necessary the stability of derivatives may also be less than the original estrogen and 
this must be studied to ensure practical laboratory workflows e.g. FMP derivatives 
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degrade following 48 hours at -20 °C but remain stable within -80°C storage [71]. 
MPPZ derivatives show minimal degradation (<15%) upon storage for 8 days in the 
autosampler and within 31 days in -20°C storage [70]. Dansyl chloride derivatives 
have been reported to be stable over a 7 day period in patient plasma [54]. However, 
in the majority of current literature, this information is lacking for many derivatization 
approaches. Derivatization techniques are still less preferred in the clinical setting, 
due to the addition of another complexity within sample preparation inevitability 
contributing toward some degree of error and to increased turn-around time. 
2.7.5 Internal Standards  
An important feature of MS analytical methods for estrogen quantification is the 
availability of stable isotope labelled internal standards (IS) giving a retention time 
match to both derivatized and non-derivatized estrogens. Addition at constant 
concentrations within the assay accounts for extraction loss at all stages.  13C-labels 
allow additional selectivity over deuterium-labelled standards, since they are highly 
unlikely to be removed during processing. Deuterium can be removed through either 
deuterium-hydrogen exchange under acidic conditions or, depending on the positions 
of the labels, during derivatization reactions. By GC and LC, the retention time of 13C-
labelled standards are well aligned whereas deuterated IS may differ slightly, 
probably due to isotope effects on hydrogen vs deuterium bonding interactions with 
the stationary phase. The slight differences in retention time that arise with deuterium 
labels are exaggerated when the number of heavy labels is increased and may lead to 
less accurate quantitation, by not compensating so well for matrix effects [103]. 
However deuterium labelled standards are applied in a number of studies generally 
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being less expensive in comparison to the 13C labelled versions [51,53,57,63,65]. 
Retention of the stable isotope labels in the product ion (quantifier ion) is desirable to 
enhance specificity, but labels can be lost in fragmentation, leaving product ions 
identical in m/z to the analyte. C3-6 labelled standards are now available for all 
estrogens shown in Figure 1. Multi-labelled standards, preferably in excess of two 
labels, e.g. 13C3 and 13C6. are desirable, to avoid interference with natural isotopologues 
[61,70]. 
3 Conclusion 
As this review highlights, there is no universal method for estrogen analysis, however 
the wide range of approaches developed over the past 10 - 15 years has allowed us to 
nudge closer to the possibility of routine investigation and monitoring of estrogen 
sensitive diseases. On comparison of technologies available, methods by GC-MS came 
to the field first and currently offer a range of limits between 0.5 – 21 pg/mL for 
estrone and estradiol in serum, plasma and urine, with 20 – 500 pg/mL for their 
metabolites. However, despite efficient resolution of isomers, GC-MS/MS is less 
favoured requiring more extensive sample preparation and the absolute requirement 
for derivatization limiting automation.  
Developments in LC-MS/MS arose more recently, with technology still advancing, 
and offer the possibility of lower detection limits of 0.14 pg/mL for standalone 
estradiol analysis with a range more commonly between 0.5 - 21 pg/mL for estrogens 
in panel assays. Although UHPLC may reduce analysis times in conjunction with MS, 
applications show similar limits of detection to conventional HPLC and GC. SPE and 
SLE extraction methods will likely lead the way forward in clinical assays due to the 
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possibility of automation. Applications involving derivatization are not universally 
superior with a number of methods not requiring derivatization now emerging that 
display similar or even lower detection capabilities. Therefore, development of 
approaches without the need for derivatization should be considered initially on 
newer instrumentation. In this setting all the possibilities of APCI and APPI modes 
have yet to be explored for the full metabolite panels. Irrespective of analytical 
technology used, the importance chromatographic development must not be 
understated due to estrogenic isomers, stereoisomers and isobaric confounders. 
Combinations of on-line SPE, high-resolution LC and MS approaches may shape the 
future for automated approaches; and ion mobility might provide a key factor in 
separation of isomers, enhancing structural confirmation in cases where shared 
product ions arise. In conclusion, advancing research into health and disease in 
clinical cohorts extending to children, men, and pre/post-menopausal women for 
disease diagnostics and monitoring means limits of analytical methods are constantly 
being tested. MS has established its place at the forefront of research into estrogen 
levels in clinical laboratories, with LC-MS/MS beginning to show potential for routine 
applications. 
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Figure Legend 
Figure 1: Endogenous steroid hormone pathway; metabolism of endogenous estrogen 
from sex hormone substrates dehydroepiandrosterone (DHEA), andostenediol (A5), 
androstenedione (A4) and testosterone (T). Oxidative metabolism of estrone (E1) and 
estradiol (E2) at C2, C4 and C16 positions by cytochrome P450 enzymes leads to the 
generation of hydroxyestrogen metabolites (2OHE, 4OHE & 16OHE). The 2OHE and 
4OHE metabolites are rapidly converted to the methoxyestrogens by catechol-O-
methyltransferases (COMT). E1 and E2 metabolites are maintained in equilibrium 
through the actions of 17β-hydroxysteroid 1 & 2 enzymes. Dysregulation in the 
balance of these metabolic pathways can harness both protective and non-protective 
roles, examples being in pathophysiology of pulmonary arterial hypertension and 
cancer. 
Figure 2: Schematic workflow for analysis of estrogens by mass spectrometry 
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